|
|
EGFR tyrosine kinase domain mutations in human
gliomas
Marie Y, Carpentier AF, Omuro AM, Sanson M, Thillet J, Hoang-Xuan K,
Delattre JY
Department of Neurology Mazarin and Institut National de la Sante et de la
Recherche Medicale UMR-495, Paris, France.
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor effective in patients with lung cancer with mutations in exons 19
and 21 of the EGFR tyrosine kinase domain.
In this study, the authors tested
the presence of such mutations in 95 gliomas including glioblastomas,
anaplastic oligodendrogliomas, and low-grade gliomas.
No mutation was found,
which suggests that the biology of EGFR in gliomas is different from lung
cancer and that this may be a factor in the resistance of glioblastomas to
gefitinib.
PMID: 15851741 [PubMed - in process]
|
